Bulllogic retweeted
Sabrina I have a new project 566K float play just hit pre split low .23 or just about 4.37, bang this one all the way to 25-30 less than cash/assets at $63 per share at 36MIL $PMCB
Bulllogic retweeted
From a reliable source.
FDA commissioner- the current front runner is Senator Roger Marshall- the same Roger Marshal who went to Mikhail to ask for Deramiocel approval. Think Mikhail will want to explain to his new boss why Deramiocel was not approve!
$capr
@houmanhemmati @Elijahjstacy
We have learned that third parties who provide services to the firm were the target of a cyber attack.
Based on our investigation so far, we believe the attackers accessed certain marketing data held by those vendors, which may include some customer names and email addresses.
There is no disruption to our services.
Where appropriate, we will contact affected customers directly and offer support, including complimentary credit monitoring.
There is no connection to service disruption some customers experienced earlier this week.
Bulllogic retweeted
The odds for $CAPR Deramiocel approval are good (60%-80%). Rationale:
1) Regulatory signals:
• FDA "lifted" its own July 2025 CRL and resumed review in March. Fierce Biotech called that highly unusual.
• After the negative adcomm, there was no second CRL on 8/22. CBER accepted a major amendment and took three more months.
2) The filing got stronger
• The indication now matches HOPE-3's primary endpoint: preservation of upper limb function. The cardiomyopathy claim the panel rejected is gone.
• Two-year open-label extension data and added robustness analyses went in with the amendment.
• 98 of 106 patients chose to continue into the open-label extension.
• The Phase 3 results were published in The Lancet: arm function declined 54% more slowly vs placebo.
3) Context
• 28 HOPE-3 physician investigators wrote to FDA leadership urging approval.
• Non-ambulant DMD is a huge unmet need.
• Adcomm votes are non-binding. FDA approved Elevidys and eteplirsen over reviewer objections.
GLTA!
Bulllogic retweeted
*ANTHROPIC IS SAID TO PRICE IPO AT $83 PER SHARE
*ANTHROPIC IS SAID TO INCREASE THE SIZE OF ITS IPO
Bulllogic retweeted
Macaulay Culkin returns as Kevin McCallister in a new McDonalds advert for the new ‘HOME ALONE’ meal.
Bulllogic retweeted
NSA's Spy Network Reportedly Goes Dark, Sending Stocks Sliding zerohedge.com/markets/nsas-s…
Bulllogic retweeted
$CAPR Everyone is talking about Tang’s exit, but has anyone noticed that RA Capital doubled its position and that Perceptive and EcoR1 initiated stakes in the company, investing several million dollars? To me, this is one of the most bullish signals from the past quarter.
Bulllogic retweeted
I ran a forensic linguistic and behavioral breakdown on CEO Linda Marbán’s Q3 earnings call ahead of $CAPR’s Nov 22 FDA decision. Looking at her exact wording, tone, and rhythm reveals three major clues:
Relaxed Q&A Rhythm (Zero Panic): Her prepared script was tight and lawyer-vetted, but in live Q&A she relaxed and joked ("I am being a little silly... right now, we are thinking we are done"). CEOs facing a hostile FDA fight or imminent CRL don't crack jokes 12 days out—it signals the review file is quiet and complete.
The "Labeling" Word Choice: When asked if heart data makes the label, she didn't say "we haven't discussed a label." She said "we are not disclosing the label information at this point"—and added whether cardiac is "in the label now or a future label expansion," signaling that a narrow upper-limb (PUL 2.0) label is the primary path.
Actions Speak Louder Than Legal Hedges: She used standard legal disclaimers ("if and when," "lucky enough"), yet $CAPR ramped Q3 spending to $44.7M to build patient support and payer access for a solo launch.
No CEO can guarantee an FDA signature, but every behavioral tell says the review reached the finish line cleanly.
Bulllogic retweeted
$CAPR FDA states continued commitment to APPROVE rare disease drugs . This happened Friday after hours . Deramiocel drug with CAPR should be next in the coming days GLTA
Longtime NBC Sports, Olympics, golf announcer Dan Hicks dies at 64 ebx.sh/CgnPng
Bulllogic retweeted
$PMCB doing a 1/19 tomorrow and fresh 500K float perma shorts here parked for months are asking for a mega squeeze like $TANH to $40 , who knows maybe they pop it prior to $1 and GTFO without forced liquidation
$NXXT is a classic example of perma shorts naked scammers getting caught pants down and getting rammed up the A$$. This is why micro nasdaq been broken with forced r/s and delists warning. Love to see that amount of pain. a 10M short here is down $20M Best thing would be 10x that
Bulllogic retweeted
$CAPR Perhaps the most overlooked moment in Linda’s Q&A:
“We’re not disclosing the label information at this point.”
Interesting choice of words, just 12 days before PDUFA.
If FDA and Capricor are already in substantive labeling negotiations, that could be an encouraging signal. Not confirmation of approval—but worth watching.





















